Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Alzheimer's Disease

  Free Subscription

Articles published in Lancet Neurol

Retrieve available abstracts of 83 articles:
HTML format

Single Articles

    September 2021
  1. THIJSSEN EH, La Joie R, Strom A, Fonseca C, et al
    Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Lancet Neurol. 2021;20:739-752.
    PubMed     Abstract available

  2. PARNETTI L, Filippo MD, Gaetani L
    A blood test for Alzheimer's disease: a step forward.
    Lancet Neurol. 2021;20:691-693.

    August 2021
  3. FAGAN AM, Henson RL, Li Y, Boerwinkle AH, et al
    Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2021;20:615-626.
    PubMed     Abstract available

  4. FRISONI GB, Hansson O
    Management of Alzheimer's disease takes a leap forward.
    Lancet Neurol. 2021;20:586-587.

  5. CARMONA-IRAGUI M, Alcolea D, Barroeta I, Videla L, et al
    Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study.
    Lancet Neurol. 2021;20:605-614.
    PubMed     Abstract available

    July 2021
    A contentious FDA ruling for Alzheimer's disease.
    Lancet Neurol. 2021 Jul 5. pii: S1474-4422(21)00215.

  7. BURNS DK, Alexander RC, Welsh-Bohmer KA, Culp M, et al
    Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet Neurol. 2021;20:537-547.
    PubMed     Abstract available

    April 2021
  8. DUBOIS B, Villain N, Frisoni GB, Rabinovici GD, et al
    Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.
    Lancet Neurol. 2021 Apr 29. pii: S1474-4422(21)00066.
    PubMed     Abstract available

    The changing definition of Alzheimer's disease.
    Lancet Neurol. 2021 Apr 29. pii: S1474-4422(21)00077.

    March 2021
  10. GRAFF-RADFORD J, Yong KXX, Apostolova LG, Bouwman FH, et al
    New insights into atypical Alzheimer's disease in the era of biomarkers.
    Lancet Neurol. 2021;20:222-234.
    PubMed     Abstract available

    January 2021
  11. SERRANO-POZO A, Das S, Hyman BT
    APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches.
    Lancet Neurol. 2021;20:68-80.
    PubMed     Abstract available

  12. KIVIPELTO M, Mangialasche F
    Dementia research in 2020: moving forward despite the COVID-19 pandemic.
    Lancet Neurol. 2021;20:3-5.

    Rapid drug access and scientific rigour: a delicate balance.
    Lancet Neurol. 2021;20:1.

    November 2020
  14. CHETELAT G, Arbizu J, Barthel H, Garibotto V, et al
    Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.
    Lancet Neurol. 2020;19:951-962.
    PubMed     Abstract available

  15. ISAACS JD, Boenink M
    Biomarkers for dementia: too soon for routine clinical use.
    Lancet Neurol. 2020;19:884-885.

    October 2020
  16. CONDELLO C, DeGrado WF, Prusiner SB
    Prion biology: implications for Alzheimer's disease therapeutics.
    Lancet Neurol. 2020;19:802-803.

  17. LAUWERS E, Lalli G, Brandner S, Collinge J, et al
    Potential human transmission of amyloid beta pathology: surveillance and risks.
    Lancet Neurol. 2020;19:872-878.
    PubMed     Abstract available

    July 2020
  18. KELLAR D, Craft S
    Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches.
    Lancet Neurol. 2020 Jul 27. pii: S1474-4422(20)30231.
    PubMed     Abstract available

    June 2020
  19. QUIROZ YT, Zetterberg H, Reiman EM, Chen Y, et al
    Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study.
    Lancet Neurol. 2020;19:513-521.
    PubMed     Abstract available

    Major risk factors for Alzheimer's disease: age and genetics.
    Lancet Neurol. 2020;19:475-476.

    May 2020
  21. KARIKARI TK, Pascoal TA, Ashton NJ, Janelidze S, et al
    Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Lancet Neurol. 2020;19:422-433.
    PubMed     Abstract available

  22. MD JH
    Can we trust The End of Alzheimer's?
    Lancet Neurol. 2020;19:389-390.

  23. JACK CR JR
    The transformative potential of plasma phosphorylated tau.
    Lancet Neurol. 2020;19:373-374.

    April 2020
  24. MCMANUS RM, Heneka MT
    T cells in Alzheimer's disease: space invaders.
    Lancet Neurol. 2020;19:285-287.

    March 2020
  25. JESSEN F, Amariglio RE, Buckley RF, van der Flier WM, et al
    The characterisation of subjective cognitive decline.
    Lancet Neurol. 2020;19:271-278.
    PubMed     Abstract available

    February 2020
    A resurrection of aducanumab for Alzheimer's disease.
    Lancet Neurol. 2020;19:111-112.

  27. CRYAN JF, O'Riordan KJ, Sandhu K, Peterson V, et al
    The gut microbiome in neurological disorders.
    Lancet Neurol. 2020;19:179-194.
    PubMed     Abstract available

    January 2020
  28. ANDREWS SJ, Fulton-Howard B, Goate A
    Interpretation of risk loci from genome-wide association studies of Alzheimer's disease.
    Lancet Neurol. 2020 Jan 24. pii: S1474-4422(19)30435.
    PubMed     Abstract available

  29. JACK CR JR
    Preclinical Alzheimer's disease: a valid concept.
    Lancet Neurol. 2020;19:31.

  30. PETERS R, Anderson CS
    Advancing dementia prevention through effective blood pressure control.
    Lancet Neurol. 2020;19:25-27.

    November 2019
  31. DING J, Davis-Plourde KL, Sedaghat S, Tully PJ, et al
    Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies.
    Lancet Neurol. 2019 Nov 6. pii: S1474-4422(19)30393.
    PubMed     Abstract available

    October 2019
  32. FRISONI GB, Ritchie C, Carrera E, Nilsson P, et al
    Re-aligning scientific and lay narratives of Alzheimer's disease.
    Lancet Neurol. 2019;18:918-919.

    August 2019
  33. LANE CA, Barnes J, Nicholas JM, Sudre CH, et al
    Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study.
    Lancet Neurol. 2019 Aug 20. pii: S1474-4422(19)30228.
    PubMed     Abstract available

    July 2019
  34. SELKOE D
    beta-secretase inhibitors for Alzheimer's disease: heading in the wrong direction?
    Lancet Neurol. 2019;18:624-626.

    June 2019
  35. FRISONI GB, Alves IL, Barkhof F
    IDEAS becoming reality on the roadmap for biomarker validation in Alzheimer's disease.
    Lancet Neurol. 2019;18:519-520.

    February 2019
  36. ARRANZ AM, De Strooper B
    The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications.
    Lancet Neurol. 2019 Feb 19. pii: S1474-4422(18)30490.
    PubMed     Abstract available

  37. WALLACE LMK, Theou O, Godin J, Andrew MK, et al
    Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the Rush Memory and Aging Project.
    Lancet Neurol. 2019;18:177-184.
    PubMed     Abstract available

    January 2019
  38. IRWIN MR, Vitiello MV
    Implications of sleep disturbance and inflammation for Alzheimer's disease dementia.
    Lancet Neurol. 2019 Jan 17. pii: S1474-4422(18)30450.
    PubMed     Abstract available

    December 2018
    Will Europe be ready for the treatment of Alzheimer's disease?
    Lancet Neurol. 2018;17:1025.

    November 2018

  40. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
    Lancet Neurol. 2018 Nov 26. pii: S1474-4422(18)30403.
    PubMed     Abstract available

    October 2018
  41. BALIN BJ, Hudson AP
    Herpes viruses and Alzheimer's disease: new evidence in the debate.
    Lancet Neurol. 2018;17:839-841.

    August 2018
  42. FORTEA J, Carmona-Iragui M, Benejam B, Fernandez S, et al
    Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Lancet Neurol. 2018 Aug 29. pii: S1474-4422(18)30285.
    PubMed     Abstract available

  43. RAFII MS
    Diagnostic biomarkers of Alzheimer's disease in Down syndrome.
    Lancet Neurol. 2018 Aug 29. pii: S1474-4422(18)30293.

  44. CARMONA S, Zahs K, Wu E, Dakin K, et al
    The role of TREM2 in Alzheimer's disease and other neurodegenerative disorders.
    Lancet Neurol. 2018;17:721-730.
    PubMed     Abstract available

  45. Jo Barnes.
    Lancet Neurol. 2018;17:667.

    July 2018
  46. MORGAN J
    No one knows what tomorrow might bring.
    Lancet Neurol. 2018;17:585.

    June 2018
  47. KNUDSEN K, Fedorova TD, Hansen AK, Sommerauer M, et al
    In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study.
    Lancet Neurol. 2018 Jun 1. pii: S1474-4422(18)30162.
    PubMed     Abstract available

    May 2018
  48. DUFOUIL C, Glymour MM
    Prediction to prevention in Alzheimer's disease and dementia.
    Lancet Neurol. 2018;17:388-389.

  49. ZIMMERMANN JF, Butler CR
    Accelerated long-term forgetting in asymptomatic APOE epsilon4 carriers.
    Lancet Neurol. 2018;17:394-395.

    April 2018
  50. FRISONI GB, Jessen F
    One step towards dementia prevention.
    Lancet Neurol. 2018;17:294-295.

    March 2018
  51. VAN DER LEE SJ, Wolters FJ, Ikram MK, Hofman A, et al
    The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study.
    Lancet Neurol. 2018 Mar 16. pii: S1474-4422(18)30053.
    PubMed     Abstract available

  52. BALLARD C, Banister C, Khan Z, Cummings J, et al
    Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Lancet Neurol. 2018;17:213-222.
    PubMed     Abstract available

    Pimavanserin for patients with Alzheimer's disease psychosis.
    Lancet Neurol. 2018;17:194-195.

    February 2018
  54. DUBOIS B, Epelbaum S, Nyasse F, Bakardjian H, et al
    Cognitive and neuroimaging features and brain beta-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Lancet Neurol. 2018 Feb 27. pii: S1474-4422(18)30029.
    PubMed     Abstract available

  55. WESTON PSJ, Nicholas JM, Henley SMD, Liang Y, et al
    Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2018;17:123-132.
    PubMed     Abstract available

    Long-term forgetting in preclinical Alzheimer's disease.
    Lancet Neurol. 2018;17:104-105.

    January 2018
  57. GORDON BA, Blazey TM, Su Y, Hari-Raj A, et al
    Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.
    Lancet Neurol. 2018 Jan 31. pii: S1474-4422(18)30028.
    PubMed     Abstract available

  58. TIJMS BM, Visser PJ
    Capturing the Alzheimer's disease pathological cascade.
    Lancet Neurol. 2018 Jan 31. pii: S1474-4422(18)30043.

  59. AUGUSTIN K, Khabbush A, Williams S, Eaton S, et al
    Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders.
    Lancet Neurol. 2018;17:84-93.
    PubMed     Abstract available

    December 2017
    Alzheimer's disease: evolution of research diagnostic criteria.
    Lancet Neurol. 2017;16:945.

    November 2017
    Pathology and hippocampal atrophy in Alzheimer's disease.
    Lancet Neurol. 2017;16:862-864.

    October 2017
  62. SOININEN H, Solomon A, Visser PJ, Hendrix SB, et al
    24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial.
    Lancet Neurol. 2017 Oct 30. pii: S1474-4422(17)30332.
    PubMed     Abstract available

    Targeting prodromal Alzheimer's disease: too late for prevention?
    Lancet Neurol. 2017 Oct 30. pii: S1474-4422(17)30372.

    September 2017
  64. JOSEPHS KA, Dickson DW, Tosakulwong N, Weigand SD, et al
    Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study.
    Lancet Neurol. 2017 Sep 11. pii: S1474-4422(17)30284.
    PubMed     Abstract available

  65. DROUIN E, Drouin G
    The first report of Alzheimer's disease.
    Lancet Neurol. 2017;16:687.

    August 2017
  66. FRISONI GB, Boccardi M, Barkhof F, Blennow K, et al
    Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.
    Lancet Neurol. 2017;16:661-676.
    PubMed     Abstract available

  67. COLEY N, Andrieu S
    Lessons from the Multidomain Alzheimer Preventive Trial - Authors' reply.
    Lancet Neurol. 2017;16:586.

  68. YASSINE HN, Schneider LS
    Lessons from the Multidomain Alzheimer Preventive Trial.
    Lancet Neurol. 2017;16:585-586.

  69. ESCOTT-PRICE V, Jones L
    Genomic profiling and diagnostic biomarkers in Alzheimer's disease.
    Lancet Neurol. 2017;16:582-583.

  70. ISAAC MT, Vamvakas S, Isaac MB
    Diagnostic biomarkers for Alzheimer's disease: a regulatory view.
    Lancet Neurol. 2017;16:580-581.

    June 2017
  71. KIRBY T
    Eric Reiman: aiming to prevent Alzheimer's disease.
    Lancet Neurol. 2017 Jun 30. pii: S1474-4422(17)30216.

    May 2017
  72. HARDY J
    Membrane damage is at the core of Alzheimer's disease.
    Lancet Neurol. 2017;16:342.

    April 2017
  73. VOSSEL KA, Tartaglia MC, Nygaard HB, Zeman AZ, et al
    Epileptic activity in Alzheimer's disease: causes and clinical relevance.
    Lancet Neurol. 2017;16:311-322.
    PubMed     Abstract available

    February 2017
    Solanezumab: too late in mild Alzheimer's disease?
    Lancet Neurol. 2017;16:97.

    January 2017
    Alzheimer's disease and other dementias: update on research.
    Lancet Neurol. 2017;16:4-5.

  76. ATTEMS J
    Alzheimer's disease pathology in synucleinopathies.
    Lancet Neurol. 2017;16:22-23.

  77. IRWIN DJ, Grossman M, Weintraub D, Hurtig HI, et al
    Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.
    Lancet Neurol. 2017;16:55-65.
    PubMed     Abstract available

    December 2016
  78. PANZA F, Logroscino G
    Anti-tau vaccine in Alzheimer's disease: a tentative step.
    Lancet Neurol. 2016 Dec 9. pii: S1474-4422(16)30340.

  79. NOVAK P, Schmidt R, Kontsekova E, Zilka N, et al
    Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Lancet Neurol. 2016 Dec 9. pii: S1474-4422(16)30331.
    PubMed     Abstract available

    October 2016
  80. RYAN NS, Nicholas JM, Weston PS, Liang Y, et al
    Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series.
    Lancet Neurol. 2016 Oct 21. pii: S1474-4422(16)30193.
    PubMed     Abstract available

    Clinical heterogeneity in familial Alzheimer's disease.
    Lancet Neurol. 2016 Oct 21. pii: S1474-4422(16)30275.

  82. TANG M, Ryman DC, McDade E, Jasielec MS, et al
    Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
    Lancet Neurol. 2016 Oct 21. pii: S1474-4422(16)30229.
    PubMed     Abstract available

    August 2016
  83. MORGAN J
    An orange and Alzheimer's disease?
    Lancet Neurol. 2016;15:911.

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.